Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of MIN-102 in healthy male volunteers
NL-OMON42947Phase 1Active, not recruiting
- Sponsor
- Minoryx Therapeutics
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of leriglitazone in adrenoleukodystrophy (ALD) (6 arms), sponsored by Minoryx Therapeutics. Started Jun 2016; status: active, not recruiting.
02
Drugs
leriglitazone
03
Conditions
adrenoleukodystrophy (ALD)
Beyond the preview
Go deeper on NL-OMON42947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42947.